What Berasil Treats: Main Uses and Benefits

Berasil (Beraprost Sodium) is an oral medication that provides supportive symptomatic relief in chronic vascular conditions. The medication is considered relevant for use in conditions that create noticeable physiological strain by affecting both systemic and pulmonary circulation, and is applied in contexts marked by increased discomfort or tension.

Easing Pain and Supporting Tissue in Peripheral Arterial Disease (PAD)

This domain covers the medication's use in patients suffering from Peripheral Arterial Disease and other chronic arterial occlusions. It is commonly used to help with symptoms related to physical discomfort, such as ischemic pain, including severe pain at rest and the pain of Intermittent Claudication. Furthermore, it is relevant for easing symptoms related to systemic imbalance and tissue damage, and may assist with managing chronic ulcerations associated with critical limb ischemia.

Quick Fact: Supports Management of Severe Ischemic Pain

---

Improving Exertional Capacity in Pulmonary Arterial Hypertension (PAH)

Berasil is generally considered relevant in the long-term symptomatic management of Pulmonary Arterial Hypertension. The medication is applied in addressing symptom clusters that create noticeable physiological strain, such as severe exertional limitation and chronic dyspnea (shortness of breath). The therapeutic benefit may assist with maintaining functional stability and contributes to easing the overall symptom burden, particularly for those in WHO Functional Classes II and III.

Eligibility Map: Who can and cannot use Berasil

Official regulatory information regarding the use of Berasil is currently not established through standard authoritative sources such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). A complete regulatory profile defining eligible and restricted populations for this specific medicine is unavailable.

---

Eligibility Scope Summary

Classification	Status based on Regulatory Documents
Populations for whom use is contraindicated	Not documented
Age-related eligibility rules	Not established (e.g., pediatric use)
Pregnancy and lactation status	Not documented
Condition-specific eligibility rules	Not established (e.g., severe hepatic or renal impairment)

---

Official Regulatory Stance

Official prescribing information for any regulated medicine, including any drug equivalent to Berasil, would explicitly list groups for whom the drug is prohibited (contraindicated) or restricted. These official classifications are based on safety data and are essential for determining patient eligibility. Without official labeling, definitive statements about who can or cannot safely use this medicine cannot be made, and use should be determined by a healthcare professional based on individual clinical risk assessment.

Interactions with other medicines and products

Berasil’s official interaction profile is structured by its core pharmacological activities and documented clearance pathways, as defined in government regulatory information.

Interaction Type	Interacting Product Classes	Official Interaction Pattern
Increased Bleeding Risk	Anticoagulants, Antiplatelet Agents, Nonsteroidal Anti-inflammatory Drugs (NSAIDs)	Co-administration results in pharmacodynamic reinforcement, significantly increasing the risk and severity of hemorrhage.
Additive Hypotension	Other Vasodilators and Antihypertensive Agents	Co-administration may lead to an excessive drop in blood pressure due to an additive vasodilatory effect.

Pharmacokinetic and Population Restrictions

The medicine's systemic clearance is a source of regulatory constraints. Beraprost Sodium is recognized as a substrate for various membrane transporters (e.g., P-gp, BCRP), which indicates a potential for altered plasma exposure when co-administered with known inhibitors of these pathways. Conversely, the drug is not expected to be involved in major interactions mediated by Cytochrome P450 enzymes.

Official regulatory information imposes population-specific restrictions: Use is contraindicated in individuals with Severe Hepatic Impairment or Severe Renal Impairment. This mandatory constraint is necessary because impaired organ function significantly reduces drug clearance, leading to elevated plasma concentrations and a heightened risk of adverse effects. No specific time-separation requirements between doses are uniformly documented.

Direct Activation of the Prostacyclin Signaling Pathway

Berasil acts as a synthetic agonist at the Prostacyclin Receptor (IP Receptor), a G s-coupled receptor located on both blood vessels and platelets. This binding initiates the central intracellular cascade by activating the Adenylate Cyclase enzyme, which increases the concentration of the key secondary messenger, cyclic AMP (cAMP). This receptor agonism initiates the molecular cascade responsible for the resulting physiological effects.

---

Dual Modulation of Vascular Tone and Blood Fluidity

The elevated cAMP levels trigger two primary and simultaneous effects. In vascular smooth muscle cells, cAMP activation leads to the reduction of intracellular calcium, causing the muscle to relax and widen the vessel (vasodilation). Concurrently, in platelets, high cAMP levels inhibit the aggregation cascade, a process that affects the viscosity of the blood. This dual mechanism—reducing vascular resistance and inhibiting platelet aggregation—is responsible for the physiological outcome of increased perfusion.

How to Use Berasil: Administration Guidelines

Berasil (Beraprost Sodium) is an oral medication that follows a structured administration protocol focused on a low starting dose and gradual adjustment. This protocol governs the appropriate systemic use of the drug for chronic vascular conditions.

---

Administration and Dosing Schedule

The approved route of administration for Berasil is oral (by mouth), utilizing the tablet formulation. The dosage regimen is centered on a titration process, where treatment begins with a low dose that is slowly increased based on individual tolerance.

The standard adult daily dose is typically divided into administrations taken multiple times per day. For indications like Chronic Arterial Occlusion, the initial daily intake may be approximately 40 mu g, with a gradual increase to a maintenance dose range of 60 mu g to 120 mu g of the active ingredient per day. The total daily dose should typically not exceed 180 mu g.

Frequency and Contextual Instructions

The dosing frequency pattern is generally three times a day (TID) in divided doses to maintain stable plasma concentrations of the active substance. This administration schedule is intended for long-term symptomatic management.

Contextual instructions specify that the tablet is usually instructed to be taken after meals (postprandial) to guide proper intake conditions. If a dose is missed, guidelines generally suggest to skip the missed dose and resume the schedule with the next planned dose; two doses should not be taken at once.

Population-Specific Use

Prescribing information also addresses high-level adjustments for specific groups. For example, careful monitoring and potential dose modification are advised for older adults and for patients with renal impairment, where a lower starting dose may be necessary due to altered drug clearance.

Research evidence / Overview of studies for Berasil

Evidence for Use in Peripheral Arterial Disease (PAD)

Research has studied Berasil in the context of symptoms associated with Peripheral Arterial Disease (PAD), a condition marked by functional limitations due to reduced blood flow. The core evidence comes from randomized, double-blind, placebo-controlled trials (RCTs), where researchers evaluated the difference between patients receiving Berasil and those receiving an inactive substance (placebo).

Studies explored how outcomes related to physical discomfort changed over the study period, which was typically 12 weeks. The two key metrics tracked were the standardized treadmill-measured pain-free walking distance and maximum walking distance. Research describes how patient-reported outcomes related to physical discomfort were monitored in the studies, including the comparison of outcomes between the Berasil group and the placebo group.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Berasil was studied for managing the functional limitations associated with PAH. The research base involves randomized, placebo-controlled trials. The main outcomes evaluated in these studies related to outcomes reflecting daily functioning or activity level, primarily using the 6-Minute Walking Distance (6-MWD) test.

These studies explored whether there was an association with changes in their overall classification of disease severity, known as the WHO Functional Class. Research explicitly tracked the comparison of outcomes between the Berasil group and the placebo group. The short-term nature of the primary efficacy assessments (often 12 weeks) means the research provides insight into short-term changes in exercise tolerance.

Evidence Consistency and Research Gaps

There are recognized research limitation frames that contribute to the broader evidence landscape. The follow-up durations were limited, which means that there is limited information for long-term outcomes or how often patients may experience a sustained response. For example, findings were mixed when comparing some functional outcomes across different international study locations. Furthermore, research continues to explore patterns related to adherence and consistency of use in daily life, as this factor was observed in some studies to influence measured outcomes.

Common questions about Berasil (FAQ)

Q: Can I take Berasil if I'm already on blood pressure medication?

A: Official regulatory documents indicate that taking Berasil alongside other vasodilators or medications used for high blood pressure (antihypertensive agents) may cause an additive effect. This combination could lead to an excessive drop in blood pressure, known as hypotension. Regulatory warnings indicate that this combination requires careful assessment and monitoring by a healthcare professional.

Q: What happens if I accidentally miss a dose of Berasil?

A: Official regulatory guidance advises that if a dose is missed, patients should simply skip that dose and resume the normal schedule with the next planned dose. Official regulatory guidance advises against taking two doses at once to compensate for a missed dose.

Q: Are there any specific foods or drinks I should avoid while using Berasil?

A: Regulatory information specifies that Berasil tablets are typically instructed to be taken after meals. While no specific foods are universally prohibited, preparations containing alcohol may enhance the medicine's side effects, particularly its blood pressure-lowering effect. Patients are advised to discuss all consumption guidelines, especially alcohol intake, with a healthcare professional.

Q: Is it normal to feel a little tired when first starting Berasil?

A: Official product information lists dizziness as a common side effect and headache as a very common side effect. These effects are often related to the drug's action of widening blood vessels (vasodilation) and can contribute to a temporary feeling of tiredness or malaise, especially when treatment is first initiated.

Q: Can children or teenagers take Berasil?

A: The safety and effectiveness of Berasil have not been fully established for use in children and adolescents. Current labeling indicates that safety and effectiveness in this age group are not established, and it is generally intended for adult use.

Q: Does Berasil affect contraception or birth control pills?

A: Official information does not uniformly document a specific interaction between Berasil and oral hormonal contraceptives (birth control pills). However, regulatory guidance generally advises caution when Berasil is used alongside any other medicinal product due to the possibility of unknown interactions.

Q: What are the serious but less common side effects of Berasil?

A: Serious adverse reactions highlighted in regulatory documents include gastrointestinal hemorrhage (severe internal bleeding). Other severe but rare effects that have been documented may include profound cardiovascular effects such as syncope (fainting) or shock, as well as cerebral hemorrhage (bleeding in the brain).

Q: What is the maximum duration Berasil is usually prescribed for?

A: Berasil is prescribed for the long-term symptomatic management of chronic vascular conditions. While primary efficacy assessments in clinical trials often lasted around 12 weeks, official regulatory labeling does not specify an absolute maximum duration for which the medicine can be used.

Q: Are there any known interactions between Berasil and alcohol?

A: Official safety information notes that consumption of alcohol may enhance the adverse effects of the medicine. This primarily relates to an increase in the drop in blood pressure (hypotension), which may lead to excessive hypotensive effects.

Q: What are the ingredients in Berasil besides the active drug?

A: Berasil tablets contain the active ingredient, beraprost sodium. Like all pharmaceutical preparations, they also contain various inactive ingredients (excipients), such as lactose, magnesium stearate, or povidone, which help form the tablet and aid in its stability.

Q: Does Berasil affect laboratory test results?

A: Official regulatory safety profiles indicate that Berasil affects the Blood and Lymphatic System. Adverse reactions such as anemia (low red blood cell count) and decreased platelet count are listed, both of which are common measurements tracked through laboratory blood tests.

Q: Are there different strengths of Berasil available?

A: Yes. Official product information confirms that Berasil is available as an oral tablet in specific strengths, such as 20 mu g or 60 mu g per tablet. These different strengths are used to support the individual dose titration and maintenance schedule required for treatment.

Q: Is Berasil a controlled substance?

A: Berasil is classified as a prescription-only medicine, meaning it requires professional authorization for use. However, official sources do not classify it as a scheduled substance under regulatory laws like the U.S. Controlled Substances Act.

Q: Can Berasil be taken with vitamins or herbal supplements?

A: While specific interactions with every vitamin or herbal supplement are not listed, official safety information advises caution. Berasil may interact with other products, and all concurrent use of supplements should be discussed with a healthcare professional.

Q: What patient populations are excluded from using Berasil?

A: Regulatory information imposes restrictions for patient safety. Berasil is restricted or contraindicated in individuals with severe hepatic (liver) impairment or severe renal (kidney) impairment because these conditions reduce the drug's clearance from the body. Caution is also mandatory for anyone with a pre-existing condition that increases the risk of bleeding.

Q: Can Berasil worsen any pre-existing health issues?

A: Yes, it may. Due to its antiplatelet effect (blood-thinning action), Berasil requires caution in patients with existing conditions that increase the risk of hemorrhage or bleeding. Its clearance pathway also mandates that individuals with severe kidney or liver impairment should be restricted from using it.

Q: Are allergic reactions to Berasil common?

A: Hypersensitivity reactions are listed in the official safety profile as uncommon, meaning they are documented but occur infrequently. Patients are advised to seek medical attention if they experience signs of a severe allergic reaction.

Q: Does Berasil affect sleep patterns?

A: Yes, it can. The regulatory safety profile lists insomnia, or difficulty sleeping, as a common adverse reaction associated with Berasil use.

Q: Does Berasil interact with any cold or flu medicines?

A: Yes, it can. Berasil interacts with certain drug classes often found in cold and flu remedies, specifically Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Co-administration with NSAIDs can significantly reinforce Berasil's antiplatelet effect, increasing the overall risk of bleeding.

Q: What if I vomit shortly after taking Berasil?

A: Official guidance for administration advises skipping a dose if it is missed and resuming the regular schedule with the next planned dose, cautioning against doubling up doses. This same principle would generally apply if the medicine is not thought to have been fully absorbed due to vomiting.

Q: Does age influence the effectiveness of Berasil?

A: Age is a factor in treatment protocols. Official prescribing information advises careful monitoring and potential dose adjustment for older adults. This modification is typically advised due to changes in drug clearance related to age, which can affect the body's overall exposure to the medicine.

Q: What are the signs that Berasil is working correctly?

A: Studies and official information indicate that Berasil's efficacy is measured by objective functional outcomes. For example, improvements were tracked in standardized tests like the pain-free walking distance for Peripheral Arterial Disease (PAD) and the 6-Minute Walking Distance (6-MWD) for Pulmonary Arterial Hypertension (PAH).

Q: What should I do if I suspect an interaction between Berasil and another product?

A: Official guidance emphasizes that patients should contact a healthcare professional if they suspect any unexpected effects or drug interactions. Severe adverse events should also be reported to the relevant national regulatory authority.

Q: Can I take Berasil during pregnancy?

A: The safety of Berasil during pregnancy is not fully established based on official regulatory documents. Use during pregnancy should only be considered when the expected therapeutic benefit is deemed to significantly outweigh the potential risks to the fetus, as determined by a healthcare provider.

Q: Is Berasil safe to use while breastfeeding?

A: It is currently not known whether Berasil is excreted into human milk. Official guidance states that the potential risks and benefits must be carefully evaluated by a healthcare professional before deciding whether to use Berasil while breastfeeding.

Storage Requirements

Berasil (Beraprost Sodium) tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), to maintain product stability. It is required to protect the medication from both light and excessive moisture.

Handling Constraint	Requirement
Container Rule	Keep the tablets in the original container and keep it tightly closed to protect integrity.
Temperature Limit	Do not freeze the product.
Child Safety	Keep out of the reach and sight of children and pets.

Disposal Instructions

Unused or expired Berasil should be disposed of in accordance with official guidance. The preferred method is using a formal drug take-back program or an authorized collection site. If no take-back option is available, the tablets may be discarded in the household trash after being mixed with an undesirable substance, sealed in a bag, and with all personal information removed from the label. The product should not be flushed down a toilet or sink.